Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Britannia Life Sciences Inc Com C.RLSC

RISE Life Science Corp is engaged in developing and evolving medical and adult hemp-based formulations to create general use of health and well-being products for the emerging consumer category. It derives key revenue from the United States.


CSE:RLSC - Post by User

Post by frenchy08on Jan 23, 2013 6:49pm
208 Views
Post# 20880618

interesting read......

interesting read......

x

FierceBiotech Special Report: China's Rise Drives Investment in Biotech Drugs
 

 

 

 



 

Until recently, the history of the pharmaceutical industry in China was more about imitation than innovation.

About 40% of biotech sales in China come from biosimilars, according to a report from London-based market researcher Scrip Intelligence. That would explain why the market for biologics in China has been growing more than 25% a year, but total sales of biotech drugs are still only $1.5 billion a year.

China’s biotech initiative is part of a broader strategy to improve the country’s healthcare system. The 5-year plan includes specific health outcomes, such as adding a year of life expectancy for the broad population and decreasing the infant mortality rate. As the size of the opportunity in China continues to expand, there’s little doubt players in the East and West will work out their differences and continue to form alliances.


 

 

Bullboard Posts